Autologous CD19-directed chimeric antigen receptor (CAR) modified T-cell therapy has improved the prognosis for adult patients with relapsed or refractory aggressive B-cell lymphomas [1–5]. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.